Thyroid Eye Disease (Graves’ Disease)

The inflammation in thyroid eye disease targets specific structures within the orbit. Activated fibroblasts produce large amounts of hyaluronic acid and other glycosaminoglycans that absorb water and swell. This expansion of fatty and connective tissue increases pressure inside the bony orbit and can push the eyeball forward, a finding called proptosis or exophthalmos. Patients with autoimmune conditions such as Sjogren syndrome may already have ocular surface compromise, making the added exposure from proptosis especially challenging.

The six muscles that control eye movement can become inflamed and thickened, restricting their ability to move the eye freely. This restriction often leads to misalignment of the eyes and double vision, particularly when looking up or to the side. In severe cases, massively enlarged muscles can compress the optic nerve at the back of the orbit.

Upper eyelid retraction is one of the most recognizable features of thyroid eye disease and results from a combination of inflammation, increased sympathetic stimulation, and scarring within the eyelid-lifting muscles. When the upper lid sits higher than normal, more of the eye surface is exposed to air, accelerating tear evaporation and contributing to persistent dryness and irritation.

Thyroid eye disease generally follows two phases. The active inflammatory phase lasts roughly one to three years, during which symptoms may fluctuate and worsen as the immune system continues to attack orbital tissues. This is followed by the stable phase, where inflammation subsides but structural changes such as proptosis, eyelid retraction, and muscle scarring may remain. Medical treatments aimed at reducing inflammation are most effective during the active phase, while reconstructive surgery is typically reserved for the stable phase.

Treatment depends on severity and disease activity. Mild cases may be managed with lubricating eye drops, cool compresses, and sunglasses to reduce glare, and choosing the right artificial tears can make a meaningful difference in daily comfort. Moderate to severe active disease may be treated with intravenous corticosteroids, orbital radiation, or targeted biologic therapy. Once the condition stabilizes, surgical options include orbital decompression, strabismus surgery, and eyelid procedures to restore function and appearance.

Yes, dry eye is one of the most common and persistent complaints in thyroid eye disease patients. Proptosis and eyelid retraction increase the exposed surface area of the eye, accelerating tear evaporation and disrupting the tear film. Inflammation within the lacrimal gland can also reduce tear production. Many patients benefit from a combination of preservative-free artificial tears, nighttime lubricating ointment, and moisture-chamber glasses.

Surgery is generally considered once thyroid eye disease has been stable for at least six months, unless an emergency such as compressive optic neuropathy or severe corneal exposure requires earlier intervention. Orbital decompression surgery removes bone or fat from the orbit to create more space and reduce proptosis. Strabismus surgery realigns the eyes to correct persistent double vision. Eyelid surgery is typically the final step.

Thyroid eye disease cannot be cured in the traditional sense because it is driven by an autoimmune process, but it can be effectively managed and, in many cases, the active phase resolves on its own over time. Medical treatments during the active phase aim to reduce inflammation and limit permanent tissue changes. Once stable, surgery can address residual proptosis, double vision, and eyelid position with excellent functional and cosmetic outcomes. Maintaining stable thyroid levels, avoiding smoking, and working closely with both an endocrinologist and an eye specialist provide the best long-term results.